Sarah Cohen, MD, Global Head of Cell Therapy Strategic Partnerships - AstraZeneca. Sarah leads high-impact academic collaborations to accelerate cell therapy and in vivo clinical programs, expand patient access, and advance next-generation cell and gene therapies across hematology, oncology, autoimmune disease, and rare conditions.
Sarah earned her medical degree from Université Paris Descartes, France, and completed her residency in pediatric hematology-oncology, followed by a fellowship in clinical immunology. She practiced in a university hospital setting for over a decade before completing a research fellowship funded by a T32 NIH grant at Boston Children's Hospital focused on dissecting novel causes of primary immune deficiency.
Prior to AstraZeneca, Sarah served as Vice President and Head of Clinical Development at Neogene Therapeutics, where she led the development of armored TCR-T cell programs targeting KRAS and TP53 in patients with solid tumors. Prior, she spent over two years at CRISPR Therapeutics, where she led the pivotal phase of allogeneic CD19-directed CAR-T programs and contributed to successful new INDs and First in Human studies for next-generation potency-enhanced allogeneic CD19 and CD70 CAR-T products in hematological malignancies and solid tumors. Earlier in her industry career, she served as clinical lead for the global Phase 3 study of Mavorixafor, a CXCR4 inhibitor developed by X4 Pharmaceuticals for WHIM syndrome — a rare primary immunodeficiency.

Sarah has built her career at the intersection of clinical medicine, translational science, and drug development – with a focus on bringing cutting edge technology into medicine. She thrives in building high-performing cross-functional teams capable of navigating complexity and ambiguity — with the aim of bringing novel and transformational therapies to patients and for keeping patients at the center of every decision.